Navigation Links
Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
Date:2/12/2008

is expected to create a drug development company with a robust pipeline of monoclonal antibody candidates in oncology, proprietary antibody discovery platforms, biopharmaceutical manufacturing capabilities and sufficient cash to fund operations at least through the end of 2009. The merger is expected to close in the first half of 2008.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Amyris Biotechnologies Announces $70 Million Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Adjusted Earnings and Backlog Increase to Record Highs, ... ), a diversified medical technologies company specializing in,diagnostics, imaging ... of women, today announced its results for the,quarter ended ... include:, -- Record revenues of $371.4 million. ...
... Product Candidate Trop-2 Signal ... Transduction Antibody -, ... full-,service biopharmaceutical development and protein production company, today,announced that it ... Inc., a biotechnology company focused on discovering,and developing the next ...
... Jan. 31 /PRNewswire-FirstCall/ - ARIUS Research Inc., ... the next wave of,antibody therapeutics, today announced ... manufacturing agreement for its Trop-2 Signal Transduction,Antibody ... and protein production company located in Princeton, ...
Cached Biology Technology:Hologic Announces First Quarter Fiscal 2008 Operating Results 2Hologic Announces First Quarter Fiscal 2008 Operating Results 3Hologic Announces First Quarter Fiscal 2008 Operating Results 4Hologic Announces First Quarter Fiscal 2008 Operating Results 5Hologic Announces First Quarter Fiscal 2008 Operating Results 6Hologic Announces First Quarter Fiscal 2008 Operating Results 7Hologic Announces First Quarter Fiscal 2008 Operating Results 8Hologic Announces First Quarter Fiscal 2008 Operating Results 9Hologic Announces First Quarter Fiscal 2008 Operating Results 10Hologic Announces First Quarter Fiscal 2008 Operating Results 11Hologic Announces First Quarter Fiscal 2008 Operating Results 12Hologic Announces First Quarter Fiscal 2008 Operating Results 13Hologic Announces First Quarter Fiscal 2008 Operating Results 14Hologic Announces First Quarter Fiscal 2008 Operating Results 15Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 2ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 3ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 4
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season ... industry as Acuity Market Intelligence reports that the ... be open. Acuity forecasts that intensifying demand for ... incorporate biometrics will drive a global market of ... devices by 2020.   According to ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... conservation successes in the face of rapid environmental change ... adapt to local climate. To improve scientists, understanding ... 2011 issue of Science helps define the ... The National Science Foundation partly funded the study, which ...
... and technologies from more than 850 scientific, technical and ... 95th Annual Meeting, Frontiers in Optics (FiO) 2011, being held ... Sainte Claire hotels in San Jose, Calif. Held in conjunction ... Physical Society (APS) Division of Laser Science (DLS), the meeting ...
... The scope and intensity of mercury pollution in ... reported, but additional mercury controls should bring needed improvement, ... the subject. Despite general declines in mercury levels ... decades, mercury concentrations still exceed human and ecological risk ...
Cached Biology News:Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 2Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 3Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 4Mercury pollution in the Great Lakes region -- nearly forgotten, but not gone 2Mercury pollution in the Great Lakes region -- nearly forgotten, but not gone 3
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... is specifically designed to target and display ... cerevisiae. Displayed proteins can be analyzed for ... putative ligands. pYD1 uses the a-agglutinin yeast ... Aga1 and Aga2 to display recombinant protein ...
... S is a member of a class of ... the DNA sequence. Mut S plays an integral ... ,replication, in transcription-coupled nucleotide excision repair and in ... Mut S binds to DNA specifically at base ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: